Correctional Medicine

Short-Course, Two-Drug Treatment For Latent TB In High-Risk Inmates Leads To Higher Completion Rates

Published in TB and Outbreaks Week, April 3rd, 2001

A new two-month, two-drug treatment for latent tuberculosis infection (LTBI) led to a marked increase in completion rates for the regimen in a high-risk jail population who had a positive tuberculin skin test, according to an article in the March 2001 issue of Chest.

Prison tuberculosis (TB) rates are six to 10 times higher than among the general public, the study notes.

For prisoners with LTBI, the current, most common treatment regimen usually lasts one year. However, since many of those who are incarcerated leave jail before completing their treatment, they return to the community with untreated LTBI. Also, a 25-site national survey...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of TB and Outbreaks Week

Source: TB and Outbreaks Week (2001-04-03)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry